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GRA1Toxoplasma gondii is a protozoan parasite that can infect warm-blooded animals including humans.
Vaccination studies mostly use tachyzoite specific proteins however in natural route of infection, toxo-
plasmosis initiates with tissue cysts (bradyzoites) or oocysts (sporozoites) and thereafter stage conver-
sion takes place where the tachyzoites take action and cause acute infection continues with
tachyzoites. Despite this knowledge, challenging models used in the vaccination studies prefer adminis-
tration of tissue cyst forming strains intraperitoneally or subcutaneously instead of oral administration
which is the natural route of infection. In the present study, a multivalent adjuvanted recombinant pro-
tein vaccine that contains bradyzoite specific BAG1 and tachyzoite specific GRA1 protein and controls
were administered to female Swiss Webster outbred mice. Humoral and cellular immune responses were
analyzed by Rec-ELISA, Western blot, and flow cytometry. Mice were infected orally with T. gondii PRU
strain tissue cysts using feeding needle to mimic the natural route of infection. 40 days after challenging
microscopy and Real Time PCR were performed to determine the protection level.
Analysis of sera obtained from vaccinated mice showed strong anti-BAG1 and anti-GRA1 IgG responses.
The IgG2a response was significantly higher (P < 0.0001) and the ratio of CD8 + T lymphocytes secreting
IFN-c almost doubled compared to PBS control which are indicative of protection against toxoplasmosis.
The amount of tissue cysts in vaccinated group was reduced 10.5% compared to control group.
To generate a protective vaccine against toxoplasmosis, multistage vaccines and usage of challenging
models mimicking natural route of infection are critical cornerstones. In this study, we generated a
BAG1 and GRA1 multistage vaccine that induced strong immune response in which the protection was
not at anticipated level. In addition, the murine model was orally challenged with tissue cysts to mimic
natural route of infection.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Toxoplasma gondii is an obligate intracellular protozoan parasite
that infects a broad range hosts including nucleated cell types from
all warm-blooded vertebrate hosts [1,2]. T. gondii infects human
and causes serious problems including congenital toxoplasmosis
in newborns which displays as malformations in unborn children,toxoplasmic retinochoroiditis which leads to blindness, and reacti-
vation of the parasite in immunologically impaired individuals
leading to fatal toxoplasmic encephalitis. Currently, toxoplasmosis
is linked to schizophrenia and other mental disorders [1,2].
T. gondii is acquired via eating tissue cyst contaminated raw meat
and water or food contaminated with oocysts released from the
infected cats. On the other hand, the veterinary importance of tox-
oplasmosis is very high, since abortion and neonatal loss in sheep
are important problems resulting with economic loss. Toxoplasmo-
sis is an important disease for not only sheep but also pigs. Trans-
mission from pork meat is one of the most important transmission
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toxoplasmosis that can be used in animals or humans is valuable.
Natural infection with T. gondii initiates with sporozoites (in
oocysts) or bradyzoites (in tissue cysts). In a couple of days, with
stage conversion, tachyzoites formed from either bradyzoites or
sporozoites expand the acute illness [5]. After the acute illness,
tachyzoites change into bradyzoites and ultimately become tissue
cysts to be dormant in tissues especially central nervous system or
retina. Although there are three stages of the parasite taking action
during the acute illness, almost all of the vaccine studies aim to
develop protection against tachyzoite form of the parasite which
invade the host cell shortly and embed themselves in a protective
parasitophorous vacuole in the host cell straightaway whereby
avoid from the host immune response. Thus, a vaccine against tox-
oplasmosis, caused by tissue cysts is required to protect the ini-
tially from bradyzoite and subsequently tachyzoite invasion and
must contain specific antigenic proteins from both stages of the
parasite.
Using recombinant proteins as vaccine antigens against toxo-
plasmosis has become popular after 1990s. Initially SAG1 which
is SRS (SAG1 related sequences) family protein presented on the
surface of the parasite and dense granule protein GRA1 were eval-
uated [6,7]. After year 2000, GRA7 and rhoptry protein ROP2 [8],
other SRS family members SAG2, SAG3, SRS1 [9], some heat shock
proteins HSP70, HSP30 (BAG1) [10], microneme proteins MIC1,
MIC2, MIC3, MIC4, MIC6 [11–14] were added to the list. Some
more dense granule proteins (GRA2, GRA4, GRA5, GRA6) [15–17],
AMA1 (Apical membrane antigen-1) [13], MAG1 (Cyst matrix
protein) [18], serine protease inhibitor-1 [19], and finally rhoptry
protein ROP4 [20] were also used as vaccine antigens. After 2010,
the variety of proteins increased rapidly by addition of more
microneme proteins (MIC8, MIC11, and MIC13) [21–23], rhoptry
proteins (ROP1, ROP5, ROP8, ROP9, ROP 13, ROP16, ROP17,
ROP18, and ROP38) [24–32], RON2, RON4 [33,34], SAG2CDX,
SAG5D, SRS4, and SRS9 from SRS family [35–38] and some others
such as PLP1 (perforin-like protein 1) [39], IMP1 (immune mapped
protein-1) [40], 14-3-3 protein [41], ROM1 (rhomboid protein 1)
[42], CDPK3 (calcium-dependent protein kinase 3) [43], eIF4A
(Eukaryotic translation initiation factor) [44], eIF2a (eukaryotic
initiation factor-2a) [45], CyP (cyclophilin), [46] cathepsin B and L
like proteases [47], aspartic protease 1 [48], cyclophilin [49], PDI
(protein disulfide isomerase) [50], ACT (Actin) [51], CDPK5
(calcium-dependent protein kinase 5) [52], DPA (Deoxyribose
Phosphate Aldolase) [53], RACK-1 (receptor for activated C kinase
1) [54], and GST (Glutathione-S Transferase) [55]. Most of these
vaccine antigens were chosen randomly without taking into
account of T. gondii’s multistage property and consequently did
not confer the desired immune responses.
Overall, development of a multivalent vaccine against different
life cycle stages of T. gondii could be more efficient. T. gondii BAG1
and GRA1 proteins have important roles in parasite’s life cycle. It is
well known that BAG1 is expressed by the bradyzoite form of the
parasite which promotes the differentiation of tachyzoites to
bradyzoites and takes role at inducing dendritic cells and activat-
ing cellular immune response [13,56,57]. GRA1 protein is
expressed by tachyzoite, bradyzoite and sporozoite forms which
is excreted to parasitophorous vacuole during the invasion of host
cell for stability of the parasite through parasitophorous network
[58]. Previously, GRA1 and BAG1 genes were used individually as
vaccine candidate antigens in DNA vaccination or recombinant
protein vaccination studies and induced protective immune
responses [7,8,10,13,18,36,59–62].
The other cornerstone to generate a protective vaccine is the
selection of appropriate challenging model. The main route of chal-
lenging differs in each study. However, naturally acquired infection
occurs through ingestion of tissue cysts and oocyst in animals andhumans [63,64]. Thus, when tissue cyst forming strains of T. gondii
are used, oral infection through curved feeding needle can be pre-
ferred which is demonstrated in this article.
In the present study, due to their active role during the invasion
of host cell as well as their immunogenic and protective efficacy in
vaccination studies, GRA1 and BAG1 proteins were selected as vac-
cine candidate antigens to generate a multivalent recombinant
protein vaccine to sequentially block the bradyzoite and tachyzoite
stages of the parasite. In addition, vaccinated and control group
mice were challenged orally with tissue cyst forming T. gondii
PRU strain to mimic natural route of infection.2. Materials and methods
2.1. Ethic statement and animal studies
All experiments were performed under the instructions and
approval of the Institutional Animal Care and Use Committee
(IACUC) of Ege University for animal ethical norms. For vaccination
studies, 6–8 weeks old female Swiss Webster outbred mice were
obtained from the Bornova Veterinary Control Institute Animal
Production Facility and housed under standard and suitable condi-
tions during the experiments.
2.2. Plasmids
pET28a/BAG1 and pET28a/GRA1 plasmids (Novagen, USA) used
to express recombinant BAG1 protein (rBAG1) and GRA1 protein
(rGRA1) were generated as described [65]. pET28a/BAG1 and
pET28a/GRA1 plasmids are transformed into E. coli BL21 Star
(DE3) pLysS chemically competent cells (Invitrogen, USA) as
described [59]. Plasmids from overnight culture were isolated
using purification kit according to the manufacturer’s protocol
(Qiagen, USA), visualized by agarose gel electrophoresis.
2.3. Protein expression and purification
E. coli BL21 Star (DE3) pLysS cells containing pET28a/BAG1 and
pET28a/GRA1 were inoculated into 500 ml LB medium supple-
mented with antibiotics (50 lg/ml kanamycin and 50 lg/ml chlo-
ramphenicol) and incubated overnight at 37 C with vigorous
shaking (220 rpm). Next day, overnight culture was inoculated to
bioreactor (Bioflo 110, New Brunswick, USA) with enrichment
medium. The dissolved oxygen and pH levels were maintained at
40–60 and 7.0 ± 0.4 with vigorous mixing (400 rpm) at 37 C until
OD600 reached 0.4. Then, the cells were induced with isopropyl-D-
thiogalactopyranoside (IPTG) to the final concentration of 0.5 mM
overnight at 18 C.
The cells were harvested by centrifugation at 5000g after 16 h
and the resuspended pellet with 50 ml pre-chilled loading buffer
(50 mM Tris–Cl pH: 7.5 and 0.3 M NaCl) was homogenized using
a blender (Waring, USA). The homogenized cells were disrupted
twice with an M-110L microfluidizer processor (Microfluidics,
USA) at a low temperature under internal pressure of 18,000 psi
and centrifuged at 30,000g for ½ h at 4 C. The clarified super-
natant was filtered through 0.45 lm filter (Corning, USA). Purifica-
tion of the protein was performed by AKTA FPLC, a liquid
chromatography system, which is controlled by UNICORNTM soft-
ware (GE Health, USA). Clarified supernatant was applied to the
HiTrap column (GE Health, USA) with loading buffer. Then, the col-
umn was washed with 125 mM imidazole containing 50 mM Tris–
Cl, pH 7.5, and 0.3 M NaCl. The recombinant proteins were eluted
by raising the imidazole concentration to 375 mM. The protein
fractions were detected by UV280, confirmed by 12% SDS–PAGE,
pooled, and concentrated with Vivaspin 20 (Sartorius, Germany)
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200 column (GE Health, USA) to remove excess endotoxin. The sub-
sequent protein fractions were pooled, concentrated and quanti-
tated by Bradford method (Pierce, USA).
2.4. Determination of endotoxin level in recombinant proteins
The amount of endotoxin in the samples was determined with
Limulus Amoebocyte Lysate (LAL) Gel-Clot test using Pyrotell sin-
gle test vials according to the manufacturer’s protocol (Associates
of Cape Cod, USA). The concentration of endotoxin-depleted,
purified rGRA1 and rBAG1 protein samples were calculated with
Bradford method (Pierce, USA) and stored at 80 C.
2.5. Vaccination and challenge
Four groups of female, 6–8 weeks old Swiss Webster outbred
mice (eleven per each group) were vaccinated intraperitoneally
twice at three weeks intervals. The first immunization group was
administered with multivalent recombinant proteins adjuvanted
with alum (Sigma Aldrich, USA) (33 lg rBAG1 + 33 lg rGRA1 in
50 ll PBS adjuvanted in 50 ll alum) according to the manufac-
turer’s protocol. Controls consisted mice groups administered only
multivalent recombinant proteins (33 lg rBAG1 + 33 lg rGRA1 in
100 ll PBS) without alum adjuvant, only alum adjuvant control
(50 ll alum adjuvant + 50 ll PBS) and PBS control (100 ll PBS)
(Table 1). For sera analysis, tail bleeds were performed three weeks
after each vaccination in anesthetized mice.
Eight mice from each group were challenged orally using a
stainless steel curved feeding needle (Harvard Apparatus, USA)
attached to 1 ml injector to mimic natural route of infection. Sus-
pension of mouse brain was prepared as previously described
[65]. Briefly, brain of a mouse infected previously with T. gondii
PRU strain tissue cysts was extracted under sterile conditions
and homogenized in approximately 2 ml sterile 0.9% NaCl contain-
ing Penicillin (10 U/ml), Streptomycin (10 lg/ml) and Gentamicin
(2 lg/ml) using an injector with 20G 100 (0.9  25 mm) needle.
Thereafter, the tissue cysts were counted under phase contrast
microscopy. For challenging, 10–12 T. gondii PRU strain tissue cysts
were administered orally to vaccinated and control group mice
nine weeks after initial vaccination.
2.6. SDS–PAGE and Western blotting of rGRA1 and rBAG1
SDS–PAGE and Western blotting of purified rGRA1 and rBAG1
proteins were performed as previously described [59]. Briefly, pro-
teins separated by 12% SDS–PAGE, were transferred to PVDF trans-
fer membrane and blocked by 6.25% non-fat dry milk containing
1xTBS-T buffer (Tris buffered saline containing Tween 20; 20 mM
Tris–Cl pH: 7.8, 0.5 M NaCl, 0.5% Tween 20) for 30 min at room
temperature. The membranes were probed with a 1:2000 dilution
of monoclonal anti-polyhistidine antibody (Sigma, USA) for 1.5 h.
Next, the membranes were probed with a 1:2500 dilution of alka-
line phosphatase-conjugated goat anti-mouse IgG (H + L) antibodyTable 1
Alum + rBAG1 + rGRA1 vaccine and control doses and routes of administration used durin
Vaccine and control groups Dose and route of administration
1st dose (day 0)
1 PBS 100 ll PBS (i.p.)
2 Alum 50 ll alum adjuvant + 50 ll PBS (i.p.
3 rBAG1 + rGRA1 33 lg rBAG1 + 33 lg rGRA1 in 100 l
4 Alum + rBAG1 + rGRA1 33 lg rBAG1 + 33 lg rGRA1 in 50 ll
in 50 ll alum (i.p.)(Sigma, USA). The blot was developed with diethanolamine buffer
(10% Diethanolamine, 0.5 mM MgCl2  6H2O, pH: 9.8) containing
4.3% 5-bromo-4-chloro-3-indolyl phosphate (diluted in dimethy-
lacetamide), 4.1% Nitro-BT (diluted in 70% (v/v) dimethylfor-
mamide) (Applichem, Germany).
2.7. Detection of humoral immune response using Western blot
To detect the anti-BAG1 and anti-GRA1 specific IgG antibody
response, rGRA1 and BAG1 proteins as well as antigen lysate pre-
pared from T. gondii Ankara strain tachyzoites were separated by
12% SDS–PAGE were transferred to PVDF transfer membrane and
blocked as described above. The membranes were incubated with
a 1:50 dilution of vaccinated mouse sera for 1.5 h. Next, the mem-
branes were incubated with a 1:2000 dilution of alkaline
phosphatase-conjugated goat anti-mouse IgG (H + L) antibody
(Sigma, USA). Thereafter, the blot was formed as described above
to visualize the immune complexes. T. gondii Ankara strain tachy-
zoites lysate was prepared as described [66] and probed to show
the presence of anti-GRA1 IgG specific to natural GRA1 protein pro-
duced by tachyzoites of all T. gondii genotypes.
2.8. Determination of IgG subclass antibody response using Rec-ELISA
Analysis of IgG1 and IgG2a subclass antibodies in vaccinated
mice sera was performed by ELISA as described [67]. Each well of
maxisorp microtiter plates (Nunc, Germany) was coated with
100 ll of recombinant protein solution (containing 5 lg/ml rBAG1
and rGRA1 in 0.01 M KCl) and incubated overnight at 4 C. Next
day, plates were washed thrice with 300 ll PBS-T and blocked (5%
nonfat dry milk containing 0.05% PBS-T) for 2 h at 37 C. Mean-
while, 1/50 and 1/100 dilutions (for the detection of IgM and IgG
antibodies, respectively) of mice sera were incubated in blocking
buffer supplemented with E. coli lysate at a final concentration of
10 mg/ml protein to block anti-E. coli antibodies with constant mix-
ing for 30 min at room temperature. Then, the plates were probed
with 100 ll blocked sera in duplicate for 2 h at 37 C. After incuba-
tion, the plates were washed thrice with 300 ll PBS-T and probed
with anti-mouse IgG1 and IgG2a conjugated with peroxidase (Jack-
son Immuno Research) at dilution of 1:1500 and 1:1000, respec-
tively for 1 h at room temperature. Bounded antibodies were
visualized after adding 100 lL 3,30,5,50 tetramethylbenzidine
(TMB) substrate. Reaction was stopped by adding 75 ll of 2 N sul-
furic acid and the results were evaluated in a micro titer plate
reader (Bio-Tek ELx808, USA) at 450 nm. Samples were considered
positive if the absorbance value (AV) of the serum sample exceeded
the mean AV + 3 S.D. of the negative control serum samples. Nega-
tive control serum samples are the day 0 of sera of mice. Each plate
contained anti-polyhistidine antibody (1:3000, Sigma, USA) probed
control wells to determine the presence of His-tagged protein.
2.9. Detection of cellular immune response
To determine the specific cellular immune response, three mice
from each group were sacrificed 3 weeks after the secondg vaccination of mice.
2nd dose (day 21)
100 ll PBS (i.p.)
) 50 ll alum adjuvant + 50 ll PBS (i.p.)
l PBS (i.p.) 33 lg rBAG1 + 33 lg rGRA1 in 100 ll PBS (i.p.)
PBS adjuvanted 33 lg rBAG1 + 33 lg rGRA1 in 50 ll PBS adjuvanted
in 50 ll alum (i.p.)
Fig. 1. (A) SDS–PAGE and (B) western blot of rGRA1 (lane 2) and rBAG1 (lane 3).
Purified protein densities of rGRA1 and rBAG1 were approximately 95% and 74%,
respectively as measured by ImageJ software. The protein ladder is from Fermentas
(USA).
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sions of splenocytes were prepared as described [59,67]. Aliquots
of 5  105 viable splenocytes were added to each well of 96 well
round bottom plate (Greiner, Germany). Before stimulation of
splenocytes, purified rGRA1 and BAG1 proteins were incubated
with polymyxin B to a final concentration of 50 lg/ml for ½ h. Cells
were stimulated with 50 lg/ml rGRA1 and BAG1 proteins for 72 h
at 37 C and 5% CO2. As positive control, splenocytes were incu-
bated with concanavalin A (Sigma, USA) at a final concentration
of 10 lg/ml. As a negative control, only growth medium was used.
During the last 4 h of incubation, monensin coming with Cyto-
fix/Cytoperm Plus Fixation/Permeabilization kit (BD Biosciences,
USA) was added to each well at a final concentration of 2 lM to
allow the intracellular accumulation of cytokines according to
the manufacturer’s protocol. T cell populations were surface
stained with Alexa flour 647 conjugated rat anti-mouse CD3 (BD
Biosciences), FITC conjugated rat anti-mouse CD4 (BD Biosciences,
USA), or FITC conjugated rat anti-mouse CD8a (BD Biosciences,
USA) using Cytofix/Cytoperm Plus Fixation/Permeabilization kit
(BD Biosciences) according to the manufacturers protocol. There-
after, the cells were permeabilized and labeled with PE conjugated
rat anti-mouse IFN-c (BD Biosciences, USA) or PE conjugated rat
anti-mouse IL-4 antibodies (BD Biosciences; USA) according to
the manufacturer’s protocol. Antibodies were diluted in
Ca+2–Mg+2 free PBS with 1% inactive FCS, 0.09% (w/v) sodium azide
(pH7.4) for surface staining and in Perm/Wash solution (BD Bio-
sciences; USA) for intracellular staining. All antibodies were used
at a final concentration of 0.5 lg/106 cells. T lymphocyte popula-
tions, gated in the flow cytometry (FACSAria; BD Biosciences;
USA) by CD3+ positive expression, were analyzed to quantify: the
percentage of rGRA1 and BAG1 proteins-specific CD8+ T lympho-
cytes secreting IFN-c and CD4+ T lymphocytes that expressed
IL-4 using FACSDiva software (BD Biosciences, USA).
2.10. Determination of protective efficacy by microscopy and Real
Time PCR
Mice administered with tissue cysts perorally as described
above were sacrificed after 42 days and thereafter T. gondii tissue
cysts and DNA were investigated in brain homogenates of mice
using phase contrast microscopy (Nikon, USA) and Real Time
PCR, respectively.
Briefly, brains of mice were extracted under sterile conditions,
homogenized in approximately 2 ml sterile 0.9% NaCl using an
injector with 20G 100 (0.9  25 mm) needle. Thereafter, the tissue
cysts were counted under phase contrast microscope as described
[65].
T. gondii AF146527 gene was investigated by Real Time PCR as
described [68]. Briefly, isolation of DNA from the mouse brain
homogenate was performed by QIAamp DNA mini kit (Qiagen,
USA) according to the manufacturer’s protocol.
During Real Time PCR, the primers used for amplifying 134 bp
AF146527 gene fragment were 50-AGGCGAGGGTGAGGATGA-30
(18nt, TOX-SE forward primer) and 50-TCGTCTCGTCTGGATCG
CAT-30 (20nt, TOX-AS reverse primer). The hybridization probes
were 50-GCCGGAAACATCTTCTCCCTCTCC-30-FL (24nt, TOX FLU,
labeled at the 30 end with fluorescein) and 50-640-CTCTCGTCGCT
TCCCAACCACG-30 (22nt, TOX LCR labeled at the 50 end with LC-
Red 640) (Metabion, Germany). The parasite quantification and
melting curve analysis was performed by 1.2 LightCycler Real Time
instrument using LightCycler software, Version 3.5 according to
the manufacturers protocol (Roche, Germany). 20 ll final volume
PCR reaction included 1 LightCycler Fast Start DNA Master HybP-
robe mix (Final concentration of MgCl2 is adjusted to 5 mM)
(Roche, Germany), 5 ll purified sample DNA template or controls.
The PCR amplification reactions were performed by the followingcalculated protocol: 10 min initial denaturation step at 95 C, fol-
lowed by 50 cycles of 5 s at 95 C, 10 s at 60 C, and 15 s at 72 C.
As positive control, T. gondii genomic DNA and one negative control
prepared by replacing template DNA with distilled water were
used. The amount of T. gondii DNA in each sample was specified
as a crossing point threshold (CPT) value. As the value of CPT
increase, the amount of T. gondii DNA in each samples decrease.
2.11. Statistical analysis
Data obtained during the experiments were processed using
Microsoft Excel 2010 and Graphpad Prism 5 program (GraphPad,
USA). A two-tailed unpaired t-test or one-way analysis of variance
with 95% confidence interval was used to determine the signifi-
cance between the vaccination groups. Humoral and cellular
immune responses and survival time were determined as
mean ± standard deviation (S.D.).3. Results
3.1. Protein expression and purification
The expression of rGRA1 and rBAG1 were induced with 0.5 mM
IPTG when growing cells reached an optical density of 0.4 at
600 nm. The cells were harvested after 16 h of induction, lysed,
and processed for purification. The rGRA1 and rBAG1 were purified
in two steps, first on a HiTrap Ni2+ chelating column and then pol-
ished on a gel filtration column. The purity of rGRA1 and rBAG1
were assessed by SDS–PAGE as shown in Fig. 1A. On SDS–PAGE
and Western blots using anti-polyhistidine monoclonal antibody,
the purified rGRA1 and rBAG1 had apparent molecular masses of
approximately 26 kDa and 30 kDa (Fig. 1B).
3.2. Humoral immune response to Alum + rBAG1 + rGRA1 vaccine
Several experiments were performed to determine the humoral
immune response to adjuvanted and control vaccinations. Initially,
rGRA1 and rBAG1 proteins as well as total T. gondii Ankara strain
tachyzoite lysate were probed with a pool of sera obtained from
each group of vaccinated mice. Strong and slightly low IgG anti-
body responses were induced by vaccination, respectively against
rGRA1 (Fig. 2A) and rBAG1 (Fig. 2B) proteins. In addition, Alum
+ rBAG1 + rGRA1 vaccine induced strong and non-adjuvanted
rGRA1 + rBAG1 containing vaccine induced slightly low IgG
Fig. 2. Western blot of (A) rGRA1 protein and T. gondii Ankara strain tachyzoite lysate and (B) rBAG1 protein probed with PBS (Lanes A2; A7; B2), Alum (Lanes A3; A8; B3),
non-adjuvanted rGRA1 + rBAG1 (Lanes A4; A9; B4) and Alum + rBAG1 + rGRA1 (Lanes A5; A10; B5) vaccinations. rGRA1 (Lane A6) and rBAG1 (B6) proteins were probed with
anti-polyhistidine antibody. The protein ladder is from Fermentas.
Fig. 3. ELISA analysis of IgG1 and IgG2a subclass antibodies elicited by Alum + rBAG1 + rGRA1 and control group vaccines. The solid black bars represent IgG2a response and
the grey bars, IgG1 response. Each bar represents the mean ± SD value of IgG2a and IgG1 responses of 11 mice from each group.
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of T. gondii tachyzoites (Fig. 2A). There was no antibody response in
control groups which were vaccinated with only Alum or PBS.
In the second set of experiments, sera from each group of
vaccinated mice were analyzed to determine the frequency of
IgG1/IgG2a polarization as the preliminary indication of whether
vaccine induced a Th1 or Th2 response. As shown in Fig. 3, Alum
+ rBAG1 + rGRA1 vaccinated mice induced significantly high levels
of IgG2a (P < 0.0001) and IgG1 (P < 0.0001) antibodies compared to
control groups, especially after the second immunization. On the
other hand, IgG2a antibody response is slightly higher than IgG1
antibody response as an indication of higher Th1 immune
response. Control groups vaccinated with only Alum or PBS had
no detectable immune response against rGRA1 and rBAG1 proteins
(Fig. 3).3.3. Cell mediated immune response to Alum + rBAG1 + rGRA1 vaccine
Splenocytes obtained from Alum + rBAG1 + rGRA1 vaccinated
and control group mice were stimulated in vitro with 50 lg/mL
purified rGRA1 and BAG1 proteins and with the mitogen ConA.
Flow cytometry analysis was used to determine the ratio of CD4+
and CD8+ T lymphocytes secreting IFN-c and IL-4 in vaccinated
and control groups. Vaccine induced IFN-c and IL-4 secretions
are indicators of Th1 and Th2 like responses, respectively. Protec-
tion against T. gondii is primarily achieved by CD8+ T lymphocytes
secreting IFN-c [4,69].
T cell population has been gated with CD3+ staining. In Alum
+ rBAG1 + rGRA1 vaccinated mice, the ratio of CD8+ T lymphocytes
secreting IFN-c increased 1.47 and 1.93 times compared to control
groups vaccinated with PBS and alum (Fig. 4C). In addition, the
Fig. 4. (A) The ratio of CD4+ T lymphocytes secreting IFN-c (B) the ratio of CD4+ T
lymphocytes secreting IL-4 (C) the ratio of CD8+ T lymphocytes secreting IFN-c.
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1.96 times compared to control groups vaccinated with PBS and
alum (Fig. 4A). On the other hand, the ratio of CD4+ T lymphocytes
secreting IL-4 increased 1.65 and 2.42 times in adjuvanted rGRA1
+ rBAG1 vaccinated mice compared to control groups vaccinated
with PBS and alum (Fig. 4B). CD3+ cells from all experimental
and control groups proliferated to comparable levels in response
to ConA.3.4. Protection conferred after oral challenge with T. gondii PRU strain
tissue cysts
In the life cycle of T. gondii, intermediate and definitive hosts are
infected through oral route. During infection T. gondii PRU strain
forms tissue cysts in mouse tissues especially in brain indicative
of chronic infection [63,64]. Thus, in the present study, Alum
+ rBAG1 + rGRA1 vaccinated and control group mice were orally
infected with 10–12 T. gondii PRU strain tissue cysts to mimic nat-
ural route of infection. The tissue cyst dosage was determined in
our previous study [65].
42 days after challenging, T. gondii tissue cysts and DNA were
investigated in brain homogenates of mice using phase contrast
microscopy and Real Time PCR. Microscopy showed that tissue
cysts in Alum + rBAG1 + rGRA1 vaccinated mice slightly decreased8.11% and 10.52% compared to control groups vaccinated with PBS
and Alum (Fig. 5A).
The CPT value of Alum + rBAG1 + rGRA1 vaccinated mice slightly
decreased 2.07% and 1.67% compared to control groups vaccinated
with PBS and alum (Fig. 5B).
4. Discussion
One of the ways of acquiring toxoplasmosis is through ingestion
of bradyzoite containing tissue cysts. Initiation of infection with
bradyzoites ends with stage conversion to tachyzoites in almost
eighteen hours [5]. Therefore, a vaccine against infection with tis-
sue cysts is required to protect the bradyzoite and subsequently
tachyzoite invasion. In the present study, a multivalent recombi-
nant protein vaccine that consists of GRA1 and BAG1 recombinant
proteins aimed to sequentially block the bradyzoite and tachyzoite
stages of the parasite.
BAG1 is a highly immunogenic protein and elicits antibody
responses against tissue cyst originated infection [70,71]. GRA1 is
also a very immunogenic protein expressed by all forms of the par-
asite [72,73]. Our previous study showed the immunogenic prop-
erties of rBAG1 and rGRA1 proteins in recently acute infection in
murine model infected orally with tissue cysts or oocysts [65].
It has been demonstrated that IFN-c secretion by CD4 Th1 and
CD8 T lymphocytes as well as antibody response is required for
effective protection against toxoplasmosis [6,22,69]. IgG2a produc-
tion from B cells is under the influence of Th1 response or low
IFN-c secretion and bias towards IgG2a response in the mice is
an indication that Th1 response is induced [59,74,75].
In the present study, Alum + rBAG1 + rGRA1 vaccine induced
strong IgG response in Swiss Webster outbred mice against rGRA1,
natural GRA1 (Fig. 2A), and rBAG1 (Fig. 2B) proteins. According
to ELISA, vaccination with adjuvanted rBAG1 + rGRA1 vaccine eli-
cited significantly high level of IgG2a as well as IgG1 antibody
response compared to controls (P < 0.0001). Marginally higher
IgG2a response compared to IgG1 response is indicative of a
slightly bias towards Th1 response (Fig. 3).
Flow cytometry analysis of Alum + rBAG1 + rGRA1 vaccinated
mice showed increment in ratio of CD8+ and CD4+ T lymphocytes
secreting IFN-c (Fig. 4). Tissue cyst and DNA load in brains of
Alum + rBAG1 + rGRA1 vaccinated mice were determined by
microscopy and Real Time PCR. In microscopy results, the tissue
cyst amount is higher in control groups. Altogether these findings
indicate that Alum + rBAG1 + rGRA1 vaccine induces Th1/Th2
mixed with the predominance of Th1 response in Swiss Webster
outbred mice.
To determine protective efficacy against toxoplasmosis, animal
models should be infected orally because definitive and intermedi-
ate hosts of T. gondii almost always get infected through oral route
in nature (except blood transfusion or laboratory accidents)
[3,4,11,16,18]. Accordingly, the protective efficacy of Alum
+ rBAG1 + rGRA1 vaccine was evaluated by infecting mice orally
with T. gondii PRU strain tissue cysts. Challenging study showed
that the amount of tissue cysts decreased to some degree however
protection against toxoplasmosis is not sufficiently conferred by
combination of these two recombinant proteins.
Previously, BAG1 and GRA1 genes were inserted to plasmids
and used against toxoplasmosis in DNA vaccination studies. A
DNA vaccine expressing GRA1 induced higher IgG2a levels than
IgG1, achieved increment in IFN-c secretion, and conferred various
levels of protection in C3H mice against oral/intraperitoneal infec-
tion with T. gondii IPB-G or 76 K strain tissue cysts [8]. In another
study, among the BAG1 and MAG1 expressing plasmids, it has been
shown that higher IgG2a response was achieved by BAG1 DNA vac-
cine and conferred some protection against oral infection with
T. gondii SSI 119 strain tissue cysts [18]. Similarly, GRA1 expressing
Fig. 5. (A) Tissue cyst and (B) DNA profiles of Alum + rGRA1 + rBAG1 vaccinated mice and control group mice vaccinated with PBS, alum or only rGRA1 + rBAG1. Mice were
challenged orally with 10–12 T. gondii PRU strain tissue cysts. The amount of tissue cyst and T. gondii DNA in brain of each mouse were determined by microscopy and Real
Time PCR. Each bar represents the mean ± SD value of Tissue cyst/100 l or CPT (Crossing point threshold) value of 8 mice from each group. As the value of CPT increase, the
amount of T. gondii DNA decreases.
Y. Gedik et al. / Trials in Vaccinology 5 (2016) 15–23 21plasmid induced higher IgG2a levels, achieved increment in IFN-c
secretion, and conferred high level of protection in C3H mice
against oral infection with T. gondii 76 K strain tissue cysts [60].
In another study, the plasmid expressing BAG1 induced high levels
of IgG2a as well as comparable levels of IFN-c secretion, however
the protection against oral challenge with T. gondii Beverley strain
was limited [13].
In studies using purified recombinant proteins, recombinant
GRA1 protein expressed by BCG, elicited strong IgG response as
well as achieved increment in IFN-c secretion in OF1 mice but con-
ferred limited protection against challenge with T. gondii 76 K
strain tissue cysts [7]. In another study, recombinant GRA1 protein
vaccine adjuvanted with Provax resulted with significant increase
in IgG2a responses, IFN-c secretion and prolonged survival in
BALB/c mice against lethal toxoplasmosis with T. gondii RH strain
tachyzoites. Interestingly, the immune response and protection
potency of rGRA1-Provax vaccine was better than GRA1 DNA vac-
cines [59]. rGRA1 was used in a trivalent SAG1 + GRA1 + MAG1
recombinant vaccine adjuvanted with Freund. Mice were chal-
lenged intraperitoneally with 10 tissue cysts of the low-virulent
T. gondii DX strain and brain cyst amount significantly decreased
89% compared to controls. The high protection level conferred in
this study shows the importance of using multivalent recombinant
protein vaccines [62].
The present study and previous studies show that rGRA1 and
rBAG1 proteins individually elicit strong immune response and
confer protection to some level against lethal toxoplasmosis with
tachyzoites or oral infection with tissue cysts [13,18,59,60] In the
present study, adjuvanted rGRA1 and rBAG1 were administered
together for the first time to mice as a multivalent recombinant
protein vaccine formulation. The aim of the multivalent vaccine
formulation was to sequentially block the bradyzoites and tachy-
zoites after stage conversion. BAG1 specific to bradyzoite stage
and GRA1 expressed by all stages of the parasite were selected
for this purpose. The results show that multivalent recombinant
BAG1–GRA1 vaccine adjuvanted with alum is a potent immuno-
genic vaccine that may induce strong immune response as shown
by significant increment in IgG levels with slight bias towards
IgG2a response as well as IFN-c secreting CD8 and CD4 cells.
Although the results are promising in terms of inducing
humoral and cellular immune responses, protection was very lim-
ited. When we analyze the reason of this modest protection in
comparison with previous vaccination studies, our protection
result sounds ordinary because the vaccination studies which con-
ferred high or full protection either used low dose parasite during
challenging or didn’t use natural route of infection. Accordingly,
none of them continued with phase studies. On the other hand,
combination of BAG1 and GRA1 recombinant proteins in a vaccineformulation may not have enough immunogenicity to increase
protection level. However, immunogenicity may be improved by
addition of more immunogenic proteins expressed by all forms of
the parasite in multivalent vaccine formulation.
There are two important actions to be taken in the route to gen-
erating a protective vaccine against toxoplasmosis. Firstly further
experiments are required to down select more immunogenic vac-
cine candidate proteins to confer stronger immune responses
[76,77]. Secondly, vaccinated animals should be infected through
natural route of infection with standard infective doses of parasite.
In future, multivalent vaccines containing more than one immuno-
genic protein formulated with various adjuvants which could
sequentially block the parasite may increase the protection against
toxoplasmosis.
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